EPIRUS Biopharmaceuticals (OTCMKTS:EPRSQ) and Achaogen (OTCMKTS:AKAOQ) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk.
Analyst Recommendations
This is a summary of current ratings and target prices for EPIRUS Biopharmaceuticals and Achaogen, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
---|
EPIRUS Biopharmaceuticals | 0 | 0 | 0 | 0 | N/A |
Achaogen | 0 | 0 | 0 | 0 | N/A |
Earnings & Valuation
This table compares EPIRUS Biopharmaceuticals and Achaogen's revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
---|
EPIRUS Biopharmaceuticals | N/A | N/A | N/A | N/A | N/A |
Achaogen | $8.73 million | 0.15 | $-186,510,000.00 | N/A | N/A |
EPIRUS Biopharmaceuticals has higher earnings, but lower revenue than Achaogen.
Risk & Volatility
EPIRUS Biopharmaceuticals has a beta of 6.03, suggesting that its stock price is 503% more volatile than the S&P 500. Comparatively, Achaogen has a beta of -0.84, suggesting that its stock price is 184% less volatile than the S&P 500.
Insider and Institutional Ownership
0.0% of Achaogen shares are owned by institutional investors. 13.1% of EPIRUS Biopharmaceuticals shares are owned by insiders. Comparatively, 7.8% of Achaogen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Profitability
This table compares EPIRUS Biopharmaceuticals and Achaogen's net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
---|
EPIRUS Biopharmaceuticals | N/A | N/A | N/A |
Achaogen | N/A | N/A | N/A |